RTx-021

About Ray Therapeutics

Ray Therapeutics is pioneering the application of optogenetics to treat blindness caused by retinal degeneration. The company's platform aims to bypass defunct photoreceptors by making surviving inner retinal neurons light-sensitive, offering a potential one-time treatment for a range of inherited and age-related retinal diseases. With its lead candidate, RTx-015, in clinical development for retinitis pigmentosa, Ray is building a seasoned leadership team to advance its pipeline. The company represents a convergence of gene therapy and neuromodulation, targeting a significant unmet medical need in ophthalmology.

About Ray Therapeutics

Ray Therapeutics is pioneering the application of optogenetics to treat blindness caused by retinal degeneration. The company's platform aims to bypass defunct photoreceptors by making surviving inner retinal neurons light-sensitive, offering a potential one-time treatment for a range of inherited and age-related retinal diseases. With its lead candidate, RTx-015, in clinical development for retinitis pigmentosa, Ray is building a seasoned leadership team to advance its pipeline. The company represents a convergence of gene therapy and neuromodulation, targeting a significant unmet medical need in ophthalmology.

Therapeutic Areas